Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7492.084 | 0.9324 | 0.9079 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7492.084 | 0.8700 | 0.8209 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7492.084 | 0.5013 | 0.2562 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7492.084 | 0.6216 | 0.4520 | 1.4850 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7493.085 | 0.9997 | 0.9995 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7493.085 | 1.1074 | 1.1489 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7493.085 | 0.9741 | 0.9635 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7493.085 | 1.0013 | 1.0019 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7493.085 | 1.0144 | 1.0203 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7493.085 | 0.9553 | 0.9366 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7493.085 | 0.9449 | 0.9217 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7493.085 | 0.6558 | 0.4860 | 1.4204 | |
| MCF7 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7493.085 | 0.0962 | -0.6152 | 1.4204 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7494.084 | 0.9543 | 0.9110 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7494.084 | 0.9355 | 0.8744 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7494.084 | 0.9723 | 0.9461 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7494.084 | 0.9543 | 0.9109 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7494.084 | 0.9399 | 0.8828 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7494.084 | 0.8989 | 0.8030 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7494.084 | 0.6785 | 0.3711 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7494.084 | 0.3813 | -0.2174 | 1.0275 | |
| MDA-MB-134-VI | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7494.084 | 0.8507 | 0.7088 | 1.0275 | |
| MDA-MB-157 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7496.085 | 0.9484 | 0.9038 | 1.0748 | |
| MDA-MB-157 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7496.085 | 0.9305 | 0.8704 | 1.0748 | |
| MDA-MB-157 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7496.085 | 0.9615 | 0.9283 | 1.0748 |